The West Highland White Terrier carries a disease burden disproportionate to its small size. Chronic allergic skin disease is so common and so characteristic in the breed that clinicians recognize it as a distinct entity. Westies are also the breed most frequently diagnosed with idiopathic pulmonary fibrosis — a progressive, fatal lung condition essentially unknown in other small breeds. Understanding these conditions, and where supplementation fits, is foundational for long-term Westie care.

Chronic Allergic Skin Disease — "Westie Itch"

Canine atopic dermatitis in Westies is a recognized clinical entity severe enough to warrant the informal label "Westie itch" in the dermatology literature. The breed's white coat is associated with lower melanin content in the skin, and reduced melanin correlates with reduced skin barrier function — specifically lower ceramide content in the stratum corneum. Ceramides are the dominant lipid in the skin barrier; their deficiency allows transepidermal water loss (TEWL) and allergen penetration, the initiating event in atopic sensitization.

The allergic cascade in Westie atopy involves IgE-mediated mast cell degranulation (histamine, prostaglandin D2, leukotriene C4) and delayed T-cell-mediated inflammation (IL-4, IL-13, IL-31 — the primary pruritus cytokine in canine atopy). Clinical signs: intense facial pruritus, paw licking, axillary and inguinal erythema, secondary lichenification from chronic scratching, recurrent otitis. Secondary infections with Malassezia pachydermatis and Staphylococcus pseudintermedius are near-universal in chronically affected dogs.

Supplement protocol for Westie atopy: omega-3 at therapeutic dose (40mg/lb EPA+DHA daily) to competitively replace arachidonic acid in mast cell membranes — reducing the prostaglandin and leukotriene response magnitude. Quercetin acts as a natural mast cell stabilizer, inhibiting degranulation and reducing histamine release. Bromelain co-administration is required — quercetin has poor bioavailability without this protease carrier. Probiotics address the gut-immune axis: Lactobacillus and Bifidobacterium strains shift gut microbiome composition toward immune regulation, reducing Th2 polarization. Timeline to measurable improvement: 8–12 weeks at consistent therapeutic dosing.

Idiopathic Pulmonary Fibrosis

Westie Lung Disease (WLD) — idiopathic pulmonary fibrosis (IPF) of West Highland White Terriers — is a progressive, irreversible interstitial lung disease characterized by fibroblast proliferation and collagen deposition in alveolar walls, replacing functional gas exchange tissue with scar. It is the canine model most analogous to human IPF, and Westies are disproportionately represented to a degree that implies a breed-specific genetic predisposition, though the causative mutation has not been precisely identified. Onset is typically middle to old age (6–13 years). Clinical signs: progressive exercise intolerance, tachypnea at rest, inspiratory crackles on auscultation, cyanosis in advanced disease. CT imaging shows the bilateral, caudodorsal, subpleural ground-glass and reticular pattern characteristic of fibrotic lung disease.

There is no curative treatment for WLD — anti-fibrotic therapies used in human IPF (pirfenidone, nintedanib) are in early investigation for canine use. Palliative management includes bronchodilators, environmental modification, and anti-inflammatory support. From a supplement standpoint: omega-3 has documented anti-fibrotic properties — EPA inhibits TGF-β1 signaling (the primary pro-fibrotic cytokine driving IPF pathology) and reduces myofibroblast differentiation. This is mechanistically relevant, though clinical evidence specific to canine pulmonary fibrosis is limited. Antioxidants (NAC is used in human IPF; vitamin E and astaxanthin in dogs) address the oxidative stress component of fibrosis. These are supportive measures in a progressive disease, not disease-modifying at a scale equivalent to pharmaceutical intervention.

Protein-Losing Enteropathy

Protein-losing enteropathy (PLE) in Westies occurs as a consequence of inflammatory bowel disease (IBD) — lymphocytic-plasmacytic enteritis is the most common histopathological form. When intestinal inflammation is sufficiently severe, gut mucosal integrity is compromised, allowing protein (albumin, globulins) to leak into the intestinal lumen and be lost in feces. Clinical consequences include hypoalbuminemia, which reduces plasma oncotic pressure and causes ascites, pleural effusion, and peripheral edema. Weight loss, diarrhea, and hypoproteinemic complications characterize advanced PLE.

PLE requires veterinary diagnosis (endoscopy and biopsy, ruling out lymphangiectasia, neoplasia) and dietary management — highly digestible, single-protein, often hydrolyzed diets. Supplement support: probiotics with prebiotic fiber (inulin, FOS) to modulate intestinal microbiome composition and reduce dysbiosis-driven mucosal inflammation. Omega-3 reduces the inflammatory burden at the intestinal mucosa — EPA and DHA compete with arachidonic acid in gut mucosal cells. Probiotic supplementation in canine IBD has documented evidence of mucosal barrier support — increased tight junction protein expression (zonulin, occludin) measured in supplemented dogs vs. controls in clinical trials.

Globoid Cell Leukodystrophy (Krabbe Disease)

Globoid cell leukodystrophy (GCL, Krabbe disease) is a fatal inherited lysosomal storage disorder caused by deficiency of galactocerebrosidase (GALC) enzyme. Without functional GALC, psychosine accumulates in oligodendrocytes, causing progressive demyelination of the central and peripheral nervous system. Inheritance is autosomal recessive — both parents must be carriers for offspring to be affected. Clinical signs begin at 2–6 months: weakness, tremors, cerebellar ataxia, visual deficits, progressive loss of motor function, death typically by 1 year. DNA testing is available and definitive — responsible breeders screen breeding stock. There is no treatment. This condition is relevant for prospective Westie buyers to understand the importance of breeder DNA testing.

The Westie supplement protocol

• Omega-3 (EPA+DHA) — highest priority; therapeutic dose for allergic skin disease and IBD/PLE mucosal support; anti-TGF-β1 relevance for pulmonary fibrosis in affected dogs
• Quercetin + bromelain — mast cell stabilization for atopic dermatitis; must be given together for bioavailability
• Probiotics with prebiotic fiber — gut-immune calibration for atopic disease; mucosal barrier support for IBD/PLE; prebiotic fiber (inulin or FOS) feeds beneficial Lactobacillus and Bifidobacterium strains
• Antioxidants (vitamin E, astaxanthin) — relevant for dogs with diagnosed pulmonary fibrosis or IBD-driven oxidative gut burden

Related: allergy supplement guide · probiotics guide · omega-3 guide · omega-3 complete guide · skin supplement guide.